Select Page
CBMG: FDA Designations for Cell Therapy to Treat DLBCL

CBMG: FDA Designations for Cell Therapy to Treat DLBCL

The U.S. Food and Drug Administration (FDA) has granted both a Fast Track Designation and a Regenerative Medicine Advanced Therapy Designation (RMAT) to Cellular Biomedicine’s (CBMG) autologous b-specific therapy, C-CAR039, for the treatment of patients with diffuse...